磁共振胰胆管成像联合血清CA125、CA19-9、CEA对良恶性梗阻性黄疸的诊断价值

摘要 目的：研究磁共振胰胆管成像（MRCP）联合血清糖类抗原125（CA125）、糖类抗原19-9（CA19-9）、癌胚抗原（CEA）对良恶性梗阻性黄疸的诊断价值。方法：将医院从2018年1月～2020年2月期间收治的90例良恶性梗阻性黄疸患者纳入研究。将其按照良恶性的差异分为良性梗阻性黄疸51例以及恶性梗阻性黄疸39例。分别对所有患者进行MRCP检测,并分析良恶性梗阻性黄疸MRCP影像学表现特征的差异。此外,采集所有患者清晨空腹静脉血,检测血清CA125、CA19-9、CEA水平并进行对比。通过受试者工作特征（ROC）曲线分析明确MRCP联合血清CA125、CA19-9、CEA对良恶性梗阻性黄疸的诊断价值。结果：恶性梗阻性黄疸部位为十二指肠乳头区人数占比明显高于良性梗阻性黄疸,而胰头上区、胰头区人数占比均明显低于良性梗阻性黄疸;且恶性梗阻性黄疸梗阻重度扩张人数占比明显高于良性梗阻性黄疸,而梗阻轻度扩张人数占比明显低于良性梗阻性黄疸,差异均有统计学意义（均P＜0.05）。恶性梗阻性黄疸患者血清CA125、CEA水平均明显高于良性梗阻性黄疸患者（均P＜0.05）;而两组血清CA19-9水平对比不明显（P＞0.05）。MRCP联合血清CA125、CA19-9、CEA诊断良恶性梗阻性黄疸的曲线下面积、灵敏度、特异度、约登指数均明显高于MRCP和血清CA125、CA19-9、CEA单独诊断。结论：MRCP联合血清CA125、CA19-9、CEA对良恶性梗阻性黄疸的诊断价值较高,值得临床推广应用。     

低位胆道恶性梗阻性黄疸术前胆红素异常的处理策略探讨(附134例报告)

目的:探讨低位胆道恶性梗阻性黄疸患者术前胆红素异常的处理策略,以提高该类患者的临床疗效。方法:回顾性分析西京医院肝胆外科2008年1月1日-2017年12月31日收治的符合研究条件的134例低位胆道恶性梗阻性黄疸(术前总胆红素≥171μmol/L)患者,按胆红素水平分为中、重度黄疸组,分析和比较两组术前黄疸的处理方法、术后肝功能、并发症情况等。结果:两组患者胆道引流后总胆红素水平均明显低于引流前,而肝功能Child-Pugh分级比较差异均无统计学意义(P0.05);两组行术前胆道引流患者与未行胆道引流患者的围手术期情况比较均无统计学差异(P0.05);两组行术前胆道引流患者与未行胆道引流患者的手术并发症的发生情况比较均无统计学差异(P0.05)。结论:对于低位胆道恶性梗阻性黄疸患者,无论中度黄疸还是重度黄疸,原则上术前不必行胆道引流。对于伴有脏器功能不全、急性炎症或其他暂不宜手术的患者,可先行胆道引流处理,限期手术。若行术前胆道引流,采用PTCD方式,更为简单安全有效。     

梗阻性黄疸与细菌／内毒素移位的关系及微生态制剂干预

梗阻性黄疸（obstructive jaundice,简称OJ,也称为外科黄疸）,是指左右肝管及其以下胆管因种种原因完全或不完全梗阻后,胆汁排泄不畅、胆汁淤积,致整个胆道系统内压增高,结合胆红素反流入血所致的全身黄染。尽管近年来梗阻性黄疸的诊断取得了长足进展,手术进行了不断革新及新一代广谱抗生素的广泛应用,梗阻性黄疸患者手术死亡率及并发症发生率仍较高。其中内毒素血症及G^-菌败血症是其主要原因。大量研究发现梗阻性黄疸存在明显的细菌及内毒素移位。本文主要论述梗阻性黄疸时肠道细菌／内毒素移位的机制及微生态制剂干预的应用前景。     

梗阻性黄疸患者经内镜逆行胰胆管造影术后胆道感染的病原菌分布、耐药性及影响因素分析

目的:探讨梗阻性黄疸患者经内镜逆行胰胆管造影(ERCP)术后胆道感染病原菌分布、耐药性以及导致术后胆道感染的影响因素。方法:选择2016年3月至2019年10月我院收治的310例行ERCP治疗的梗阻性黄疸患者,根据ERCP术后是否发生胆道感染将其分为感染组(50例)和未感染组(260例)。检测胆道感染患者病原菌种类及其耐药性,多元Logistic回归分析影响梗阻性黄疸患者ERCP术后胆道感染的影响因素。结果:ERCP术后胆道感染发生率为16.13%,大肠埃希菌、铜绿假单胞菌、粪肠球菌、屎肠球菌是主要致病菌,检出率分别为40.79%、13.16%、9.21%、6.58%。大肠埃希菌、铜绿假单胞菌对头孢类、氨基糖苷类抗生素耐药率高,粪肠球菌、屎肠球菌对利福平、喹诺酮类抗生素耐药率高,大肠埃希菌、铜绿假单胞菌、粪肠球菌、屎肠球菌均对利奈唑胺、亚胺培南敏感。多元Logistic回归分析结果显示,恶性病变、ERCP2次及以上、胆胰管汇流异常、术后胆管引流不畅是梗阻性黄疸患者ERCP术后胆道感染的危险因素(P0.05),术后预防性使用抗生素是保护因素(P0.05)。结论:梗阻性黄疸患者ERCP术后存在一定胆道感染风险,革兰氏阴性菌是主要致病菌,临床应注重对高危因素预防,有必要术后选择敏感抗生素预防性治疗。     

两种不同手术方式治疗恶性梗阻性黄疸患者的临床疗效比较研究

目的:探讨经皮肝穿刺胆管引流术(PTCD)与经内镜逆行胰胆管造影术(ERCP)治疗恶性梗阻性黄疸的治疗效果,并进行比较分析。方法:选取2016年1月~2018年5月期间我院收治的127例恶性梗阻性黄疸患者。根据治疗术式的不同将患者分为ERCP组(n=63,采用ERCP联合金属支架置入术进行治疗)和PTCD组(n=64,采用PTCD进行治疗),比较两组患者术后5d黄疸缓解率,比较两组患者术前、术后2周肝功能指标[血清总胆红素(TBIL)、丙氨酸转氨酶(ALT)、直接胆红素(DBIL)],比较两组患者术后舒适度量表评分情况及并发症发生情况。结果:两组患者术后黄疸总缓解率比较差异无统计学意义(P0.05);PTCD组低位梗阻患者黄疸缓解率低于ERCP组,而高位梗阻患者黄疸缓解率高于ERCP组(P0.05)。两组患者术前、术后2周TBIL、ALT、DBIL比较差异无统计学意义(P0.05);两组患者术后2周TBIL、ALT、DBIL水平较术前比较均下降(P0.05)。ERCP组患者术后舒适度量表评分总分低于PTCD组,差异有统计学意义(P0.05)。PTCD组术后并发症总发生率14.06%(9/64),低于ERCP组的41.27%(26/63)(P0.05)。结论:ERCP与PTCD治疗恶性梗阻性黄疸均可改善患者肝脏功能、疗效满意,但ERCP对低位梗阻患者治疗效果优于PTCD,且术后舒适度优于PTCD,但术后并发症较多,临床应根据患者情况选择具体术式。     

减黄治疗后早期胆管炎的相关因素分析

摘要 目的：探讨恶性梗阻性黄疸患者接受减黄治疗后早期胆管炎的相关因素。方法：回顾性分析自2013年1月至2020年7月上海瑞金医院北部院区普外科收治的恶性梗阻性黄疸患者的临床资料,根据减黄治疗后2周内是否发生胆管炎分为早期胆管炎组与非早期胆管炎,采用SPSS 21.0统计软件进行数据分析处理。结果：共入组69例临床资料,男性40例,女性29例,减黄治疗后早期发生胆管炎者17例,中位时间3（2, 11.5）天。两组患者在年龄、性别、病程、总胆红素、引流方式上未发现统计学差异,而引流物直径、胆道梗阻部位存在统计学差异（P＜0.05）,进一步Logistic回归分析提示引流物直径是减黄治疗后发生早期胆管炎的相关因素[OR=0.889, 95% CI（0.792, 0.998）,P=0.046]。结论：恶性梗阻性黄疸行减黄治疗时,应选择直径较大的引流物,对胆道进行充分、有效的引流,可减少减黄治疗后早期胆管炎的发生。     

84例梗阻性黄疸的B型超声诊断

B超诊断梗阻性黄疽可分为定性、定位和病因检查三部分,前两者诊断正确率较高,但病因诊断正确率却令人不满意。近年来随着高分辨力的超声诊断仪应用于临床及操作方法的改进,使梗阻性黄疽的病因正确诊断率得到了一定的提高。本院近年来经手术病理结果证实84例梗阻性黄疽,现总结报告如下:资料和方法1资料本组84例均为我院住院病人,男性58例,女性26例,年龄26-76岁。临床诊断梗阻性黄疸72例,黄疸型肝炎8例,临床无黄疸表现诊断为胆囊炎做B超检查时发现胆管扩张4例,表现为进行性黄疽加深32例,间歇性黄疸42例,轻微黄疽6例。2方法:采用美国惠普一彩…     

经皮肝穿刺胆道引流术与逆行胰腺胆管造影术对结石性梗阻性黄疸患者的疗效比较研究

目的:比较经皮肝穿刺胆道引流术(PTCD)与逆行胰腺胆管造影术(ERCP)对结石性梗阻性黄疸患者的治疗效果。方法:选取海军军医大学第三附属医院东方肝胆外科医院于2016年3月～2018年4月间收治的结石性梗阻性黄疸患者80例。按照介入治疗术式的异同将患者分为ERCP组(n=40,给予ERCP治疗)和PTCD组(n=40,给予PTCD治疗),记录两组手术时间、术中出血量、住院费用、住院时间、治疗成功率、黄疸缓解率、并发症发生情况,比较两组术前、术后1 d、术后7 d肝功能指标情况。结果:两组患者手术时间、术中出血量、治疗成功率、黄疸缓解率比较差异无统计学意义(P0.05),ERCP患者住院费用少于PTCD组患者,住院时间亦短于PTCD组患者(P0.05)。两组患者术后1 d、术后7 d丙氨酸转氨酶(ALT)、总胆红素(TBIL)、直接胆红素(DBIL)水平均较术前降低,且两组患者术后7 d上述指标水平低于术后1 d(P0.05),ERCP组术后1 d、术后7 d ALT、TBIL、DBIL水平与PTCD组比较差异无统计学意义(P0.05)。两组患者术后并发症总发生率比较差异无统计学意义(P0.05)。结论:PTCD、ERCP治疗结石性梗阻性黄疸,均能有效改善患者临床症状和肝功能,且手术安全性相当,但ERCP可明显减少住院时间和住院费用。     

胆道支架植入治疗恶性梗阻性黄疸术后并发症的发生因素分析

摘要 目的：探讨与分析胆道支架植入治疗恶性梗阻性黄疸术后并发症的发生因素。方法：采用回顾性总结研究方法,2015年10月-2019年10月选择在本院重症监护病房(Intensive Care Unit,ICU)诊治的恶性梗阻性黄疸患者112例,所有患者都给予胆道支架植入治疗,记录术后感染并发症发生情况。调查患者的临床资料并进行影响因素分析。结果：112例患者术后发生感染并发症18例,发生率为16.1 %,其中胆道感染5例,肺部感染4例,切口感染9例。112例患者术后7 d的血清介素-6(inter-leukin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、谷草转氨酶(aspartate aminotransferase,AST)、谷丙转氨酶(alanine transaminase,ALT)值低于术前,CD4⁺细胞比例高于术前(P<0.05),CD8⁺细胞比例在手术前后对比差异无统计学意义(P>0.05)。Pearson分析显示术后感染与APACHEⅡ评分、住院时间、糖尿病、吸烟、术前IL-6值、术前CD4⁺细胞比例存在相关性(P<0.05)。Logistic回归分析显示APACHEⅡ评分、住院时间、糖尿病、吸烟、术前IL-6值、术前CD4⁺细胞比例导致患者术后感染发生的主要影响因素(P<0.05)。结论：胆道支架植入治疗恶性梗阻性黄疸能抑制炎症因子的释放,促进恢复患者的免疫功能,改善患者的肝功能,但伴随有感染并发症的发生,APACHEⅡ评分、住院时间、糖尿病、吸烟、术前IL-6值、术前CD4⁺细胞比例是导致患者术后感染发生的主要影响因素。     

急性胰腺炎患者腹腔镜胆囊切除术的时机研究

目的:探讨急性胰腺炎胆囊切除术的有效性及时机。方法:分别对患有急性胰腺炎而进行腹腔镜胆囊切除的38例患者的临床信息进行了研究。结果:首先对38例病人进行了3~15天非手术的保守治疗,当临床症状和表征基本消失,血、尿中的淀粉酶接近正常水平时,进行胆囊切除。手术时间为30分钟到90分钟(平均时间60分钟),手术中无转化和严重并发症症状发生。对这38例病人随访6到56周后无复发现象发生。结论:当临床症状和表征基本消失,血、尿中的淀粉酶接近正常水平时,急性胰腺炎胆囊切除术是有效且可行的。在中国患有急性胰腺炎的患者中,进行腹腔镜胆囊切除的占50%~70%[1]。胆结石治疗取决于患者胰腺炎的严重性,及患者是否患有梗阻性黄疸。对于非梗阻性胰腺炎的患者,早期是否要进行明确的手术治疗尚无定论。我院患有急性胰腺炎的38例患者进行腹腔镜胆囊切除术(2004年2月到2009年4月之间)后取得了满意的效果。详情如下。     

Pruritus and Jaundice

The records of 147 patients who had pruritus and jaundice (11% of a series of 1262 patients with jaundice) were reviewed in an effort to delineate more clearly the etiology of jaundice associated with pruritus.Fifty-two had obstructive jaundice caused by neoplasm, 51 had obstructive jaundice not caused by neoplasm, 42 had pruritus associated with hepatogenous jaundice, and two had jaundice and pruritus associated with a lymphoma.Pruritus occurred in 17% of all patients with non-neoplastic obstructive jaundice and in 45% of patients with neoplastic obstructive jaundice. Hepatogenous jaundice was the cause of pruritus in almost one-third of the patients in this series-occurring in 20% of patients with infectious hepatitis and in 7% of patients with cirrhosis.This large series confirms the clinical impression that pruritus occurs most often in association with extrahepatic biliary obstruction, and as well re-emphasizes the common association of pruritus with hepatogenous jaundice.     

Diagnostic Performance of Magnetic Resonance Cholangiopancreatography in Malignant Obstructive Jaundice

Malignant obstructive jaundice is caused by tumors arising from the head of the pancreas and biliary tree, or seen due to secondary metastases in the porta hepatis lymph nodes. Magnetic resonance cholangiopancreatography (MRCP) is a non-invasive diagnostic technique that can be used for imaging the entire biliary tree and pancreatic duct system. The objective of this study was to evaluate the accuracy of MRCP in the diagnosis of malignant obstructive jaundice. The methods used involved comparative review of the images obtained by using magnetic resonance imaging and MRCP as well as comparison between MRCP- and pathology-based diagnoses. The accuracy of MRCP-based diagnosis of malignant obstructive jaundice was analyzed. Our data show that the positive rate of anatomical diagnosis and the detection rate of bile ducts on the proximal side of obstruction are 100%. The diagnostic accuracy of malignant obstruction was 82.9%. MRCP was found to have high diagnostic specificity for determining the location and extent of obstruction. We, therefore, concluded that MRCP had significance for clinical diagnosis of malignant obstructive jaundice. The positive rate of localization diagnosis was 100%. Distinguishing the quality of obstruction was also important. The diagnostic accuracy of MRCP for malignant obstructive jaundice was remarkably higher.     

腹腔镜胃癌根治术的研究进展

胃癌是全球发病率较高的恶性肿瘤之一,且发病率呈逐年上升的趋势。传统的治疗方法是开腹胃癌根治术,但该方法对患者机体造成的创伤较大,不利于患者术后恢复,在一定程度上影响了手术治疗的效果。随着医学技术的发展及"微创外科"理念的不断深入,腹腔镜手术以其创伤小、术中出血量少以及术后恢复快等特点被广泛应用于外科手术治疗中。近年来,3D腹腔镜技术的出现使手术视野更加清晰,术中操作更加简便,在一定程度上提高了手术的安全性,但临床对于进展期胃癌根治术的远期疗效一直存在争议。因此,本文对腹腔镜在胃癌根治术中的作用及意义作以综述,为胃癌的微创治疗提供理论参考。     

Cholesterol and its esters as serum biomarkers in malignant obstructive jaundice: a single step 1H NMR metabolomic approach

The paucity of biomarkers for malignant obstructive jaundice results in formidable morbidity and mortality rates. Therefore, alternative diagnostic measures are required for improved clinical interpretation and better peri-operative management of patients. In the present study, ¹H NMR-based metabolomic approach has been applied to investigate serum and bile based metabolic biomarkers in benign and malignant causes of obstructive jaundice (OBJ). Serum and bile specimens from benign OBJ patients (n = 28), malignant OBJ patients (n = 36) and serum of healthy controls (n = 57) were analysed by ¹H NMR spectroscopy. Quantitation of eight serum metabolites (isobutyrate, lactate, alanine, acetone, glutamine, creatine, threonine and 1-methylhistidine) was carried out. A newer and rapid single step NMR based semi-quantitative ratio analysis of serum total cholesterol (tCho), cholesterol (Chol) and cholesterol ester (CE) were performed in deuterated dimethyl sulfoxide-d₆. In bile, total bile acids, cholesterol, phosphatidylcholine, glycerophosphatidylcholine and urea were quantified. The effect of benign and malignant OBJ on small metabolites and lipids were statistically analysed by Mann–Whitney U test and multivariate discriminant function analysis. It was found that malignancy could be differentiated from benign cases of OBJ with a correct classification of 85.7 % when eight serum metabolites in combination with ratios of serum cholesterol were analysed. Significant alterations in serum tCho, Chol, CE and serum metabolites may have potential for early and differential non-invasive diagnosis of malignant and benign OBJ cases. It will further augment the novel insights of local and systemic effects in OBJ patients.     

内镜下逆行胰胆管造影置放胆道支架治疗恶性梗阻性 黄疸98 例疗效分析

目的:探讨内镜下逆行胰胆管造影置放胆道支架对恶性胆道梗阻的疗效及并发症的防治。方法:选择2008年2月至2011年9月我院收治的无法手术切除或不愿手术的恶性胆道梗阻患者98例,通过放置内置支架引流观察其操作成功率、支架通畅期和退黄效果、并发症发生情况及其防治效果和患者生存期等。结果:98例患者中有88例成功通过置入胆道内置引流管,成功率为89.8%,并发症发生率为11.22%,所有成功患者术后1周黄疸明显减退,支架平均通畅期137天,患者平均生存期为163天。结论:行胆道内置支架引流创伤小,并发症少,通畅性能好,可持久有效地控制黄疸,有效缓解病情,改善全身情况,明显延长恶性胆道梗阻患者的生存期。     

CA 19-9 assay in patients with extrahepatic cholestatic jaundice

Serum concentrations of the CA 19-9 tumour marker were determined in 35 patients with histologically proven bilio-pancreatic malignancies associated with obstructive jaundice and in 35 patients with benign extrahepatic jaundice due to choledocholithiasis. At a cut-off level of 37 U/ml the sensitivity of this assay was 82.8%, but the specificity was very low (45.7%). Thus CA 19-9 can not be employed to differentiate between malignant and benign extrahepatic jaundice. Serial samples of CA 19-9 were achieved in 7 patients with benign and in 6 patients with malignant biliary obstruction, before and after the disappearance of jaundice. Serum concentrations of this tumour-antigen returned to normal concurrently with the bilirubin values only in patients with benign obstruction, remaining unchanged in all cases of malignancies. The data suggest that patients with extrahepatic jaundice should be evaluated by other examinations or by collecting serial samples for this assay.